Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat

Antiviral Research

Volumn 87, Issue 2, 2010, Pages 179-186

  Izumi, Kazuki ^a   Nakamura, Shota ^b   Nakano, Hiroaki ^b   Shimura, Kazuya ^a   Sakagami, Yasuko ^a   Oishi, Shinya ^a   Uchiyama, Susumu ^b   Ohkubo, Tadayasu ^b   Kobayashi, Yuji ^b   Fujii, Nobutaka ^a   Matsuoka, Masao ^a   Kodama, Eiichi N ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amino terminus; Fusion; Gp41; HIV 1; Resistance

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; N 36; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEPTIDE C34; PEPTIDE FRAGMENT; PEPTIDE N36;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CHEMICAL ANALYSIS; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE; X RAY CRYSTALLOGRAPHY; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECTS; GENETICS; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN DENATURATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; VIRUS ENTRY;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CRYSTALLOGRAPHY, X-RAY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV-1; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PROTEIN DENATURATION; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954956891     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.04.011     Document Type: Article

References (51)

1. Aquaro S., D'Arrigo R., Svicher V., Di Perri G., Lo Caputo S., Visco-Comandini U., Santoro M., Bertoli A., Mazzotta F., Bonora S., Tozzi V., Bellagamba R., Zaccarelli M., Narciso P., Antinori A., Perno C.F. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J. Antimicrob. Chemother. 2006.
2. Armand-Ugon M., Gutierrez A., Clotet B., Este J.A. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res. 2003, 59(2):137-142.
3. Bai X., Wilson K.L., Seedorff J.E., Ahrens D., Green J., Davison D.K., Jin L., Stanfield-Oakley S.A., Mosier S.M., Melby T.E., Cammack N., Wang Z., Greenberg M.L., Dwyer J.J. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure. Biochemistry 2008.
4. Baldwin C.E., Sanders R.W., Deng Y., Jurriaans S., Lange J.M., Lu M., Berkhout B. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 2004, 78(22):12428-12437.
5. Bianchi E., Finotto M., Ingallinella P., Hrin R., Carella A.V., Hou X.S., Schleif W.A., Miller M.D., Geleziunas R., Pessi A. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(36):12903-12908.
6. Bienvenu B., Krivine A., Rollot F., Pietri M.P., Lebault V., Meritet J.F., Guerin C., Spiridon G., Salmon D., Guillevin L., Lebon P., Launay O. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. J. Med. Virol. 2006, 78(10):1312-1317.
7. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D: Biol. Crystallogr. 1998, 54(Pt 5):905-921.
8. Cabrera C., Marfil S., Garcia E., Martinez-Picado J., Bonjoch A., Bofill M., Moreno S., Ribera E., Domingo P., Clotet B., Ruiz L. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006, 20(16):2075-2080.
9. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(26):15613-15617.
10. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89(2):263-273.
11. Desmezieres E., Gupta N., Vassell R., He Y., Peden K., Sirota L., Yang Z., Wingfield P., Weiss C.D. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. J. Virol. 2005, 79(8):4774-4781.
12. Dubay J.W., Roberts S.J., Brody B., Hunter E. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. 1992, 66(8):4748-4756.
13. Dwyer J.J., Wilson K.L., Martin K., Seedorff J.E., Hasan A., Medinas R.J., Davison D.K., Feese M.D., Richter H.T., Kim H., Matthews T.J., Delmedico M.K. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci. 2008, 17(4):633-643.
14. Dwyer J.J., Wilson K.L., Davison D.K., Freel S.A., Seedorff J.E., Wring S.A., Tvermoes N.A., Matthews T.J., Greenberg M.L., Delmedico M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(31):12772-12777.
15. Eckert D.M., Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(20):11187-11192.
16. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 2001, 70:777-810.
17. Eggink D., Baldwin C.E., Deng Y., Langedijk J.P., Lu M., Sanders R.W., Berkhout B. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 2008, 82(13):6678-6688.
18. Eron J.J., Gulick R.M., Bartlett J.A., Merigan T., Arduino R., Kilby J.M., Yangco B., Diers A., Drobnes C., DeMasi R., Greenberg M., Melby T., Raskino C., Rusnak P., Zhang Y., Spence R., Miralles G.D. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis. 2004, 189(6):1075-1083.
19. Fikkert V., Cherepanov P., Van Laethem K., Hantson A., Van Remoortel B., Pannecouque C., De Clercq E., Debyser Z., Vandamme A.M., Witvrouw M. Env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob. Agents Chemother. 2002, 46(12):3954-3962.
20. Heredia A., Gilliam B., DeVico A., Le N., Bamba D., Flinko R., Lewis G., Gallo R.C., Redfield R.R. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS 2007, 21(10):1317-1322.
21. Hermann F.G., Egerer L., Brauer F., Gerum C., Schwalbe H., Dietrich U., von Laer D. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J. Virol. 2009, 83(10):4844-4853.
22. Izumi K., Kodama E., Shimura K., Sakagami Y., Watanabe K., Ito S., Watabe T., Terakawa Y., Nishikawa H., Sarafianos S.G., Kitaura K., Oishi S., Fujii N., Matsuoka M. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J. Biol. Chem. 2009, 284(8):4914-49120.
23. Kahle K.M., Steger H.K., Root M.J. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 2009, 5(11):e1000674.
24. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1998, 4(11):1302-1307.
25. Kinomoto M., Yokoyama M., Sato H., Kojima A., Kurata T., Ikuta K., Sata T., Tokunaga K. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J. Virol. 2005, 79(10):5996-6004.
26. Kuiken C., Leitner T., Foley B., Hahn B., Marx, McCutchan F., Wolinsky S., Korber B. HIV sequence compendium, 2009. Theoretical Biology and Biophysics Group 2009, Los Alamos National Laboratory, Los Alamos, NM.
27. Labrosse B., Morand-Joubert L., Goubard A., Rochas S., Labernardiere J.L., Pacanowski J., Meynard J.L., Hance A.J., Clavel F., Mammano F. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 2006, 80(17):8807-8819.
28. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348(22):2175-2185.
29. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., Katlama C., Stellbrink H.J., Delfraissy J.F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003, 348(22):2186-2195.
30. Lohrengel S., Hermann F., Hagmann I., Oberwinkler H., Scrivano L., Hoffmann C., von Laer D., Dittmar M.T. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J. Virol. 2005, 79(16):10237-10246.
31. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995, 2(12):1075-1082.
32. Lu M., Ji H., Shen S. Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J. Virol. 1999, 73(5):4433-4438.
33. Lu M., Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 1997, 15(3):465-471.
34. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 1999, 125(2-3):156-165.
35. Menzo S., Castagna A., Monachetti A., Hasson H., Danise A., Carini E., Bagnarelli P., Lazzarin A., Clementi M. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents Chemother. 2004, 48(9):3253-3259.
36. Mink M., Mosier S.M., Janumpalli S., Davison D., Jin L., Melby T., Sista P., Erickson J., Lambert D., Stanfield-Oakley S.A., Salgo M., Cammack N., Matthews T., Greenberg M.L. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 2005, 79(19):12447-12454.
37. Nameki D., Kodama E., Ikeuchi M., Mabuchi N., Otaka A., Tamamura H., Ohno M., Fujii N., Matsuoka M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 2005, 79(2):764-770.
38. Nishikawa H., Nakamura S., Kodama E., Ito S., Kajiwara K., Izumi K., Sakagami Y., Oishi S., Ohkubo T., Kobayashi Y., Otaka A., Fujii N., Matsuoka M. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int. J. Biochem. Cell Biol. 2009, 41(4):891-899.
39. Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., Fujii N. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl. 2002, 41(16):2937-2940.
40. Perez-Alvarez L., Carmona R., Ocampo A., Asorey A., Miralles C., Perez de Castro S., Pinilla M., Contreras G., Taboada J.A., Najera R. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J. Med. Virol. 2006, 78(2):141-147.
41. Ray N., Harrison J.E., Blackburn L.A., Martin J.N., Deeks S.G., Doms R.W. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 2007, 81(7):3240-3250.
42. Rimsky L.T., Shugars D.C., Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 1998, 72(2):986-993.
43. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., Pohlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., Doms R.W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(25):16249-16254.
44. Steger H.K., Root M.J. Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 2006, 281(35):25813-25821.
45. Tolstrup M., Selzer-Plon J., Laursen A.L., Bertelsen L., Gerstoft J., Duch M., Pedersen F.S., Ostergaard L. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS 2007, 21(4):519-521.
46. Ueno M., Kodama E.N., Shimura K., Sakurai Y., Kajiwara K., Sakagami Y., Oishi S., Fujii N., Matsuoka M. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Res. 2009, 82(1):67-72.
47. Vagin A., Teplyakov A. MOLREP: an Automated Program for Molecular Replacement. J. Appl. Crystallogr. 1997, 30(Pt 6):1022-1025.
48. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46(6):1896-1905.
49. Wild C., Dubay J.W., Greenwell T., Baird T., Oas T.G., McDanal C., Hunter E., Matthews T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(26):12676-12680.
50. Wild C., Greenwell T., Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 1993, 9(11):1051-1053.
51. Wild C., Oas T., McDanal C., Bolognesi D., Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(21):10537-10541.